Chiasma is focused on improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. The company's proprietary Transient Permeability Enhancer (TPEÂŽ) technology platform is designed to enable the intestinal absorption of molecules that would otherwise have limited intestinal bioavailability. The company is developing octreotide capsules (conditionally trade named MycapssaÂŽ) for the potential maintenance treatment of adult patients with acromegaly. The company completed an international Phase 3 trial of octreotide capsules, the results of which have been published in the Journal of Clinical Endocrinology and Metabolism.
Source
